AFP and neoplasm: Following successful downstaging, that is no extrahepatic disease, an AFP cutoff, and PET non-avid tumor, and response to downstaging therapy to guarantee acceptable tumor biology, patients with proven HCC with macrovascular invasion may be eligible for LDLT [54].